Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
J Zhejiang Univ Sci B. 2013 Mar;14(3):207-15. doi: 10.1631/jzus.B1200101.
The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods.
The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival.
Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.
本研究旨在评估亚甲基四氢叶酸还原酶（MTHFR）C677T 切除修复交叉互补组 1（ERCC1）基因多态性与吉西他滨为基础的化疗在晚期非小细胞肺癌（NSCLC）中的临床疗效之间的关系。
共 135 例未经手术的晚期 NSCLC 患者接受吉西他滨/铂类方案化疗。采用 TaqMan 方法检测 MTHFR C677T、ERCC1 C8092A 和 ERCC1 C118T 多态性。
总缓解率为 28.9%。MTHFR CC 基因型患者的客观缓解率高于变异基因型（TT 或 CT）患者（41.2%比 19.1%，P=0.01）。MTHFR CC 基因型患者的中位无进展生存期（TTP）长于变异基因型患者（7.6 个月比 5.0 个月，P=0.003）。ERCC1 C118T 和 C8092A 多态性与反应和生存均无显著相关性。
我们的数据表明，MTHFR C677T 多态性可能是吉西他滨/铂类治疗晚期 NSCLC 患者反应和 TTP 的预测标志物。
